

Department of Transfusion Medicine Major Publications 2001

Adams SD, Barracchini KC, Simonis TB, Stroncek D, Marincola FM. High throughput HLA sequence-based typing (SBT) utilizing the ABI Prism (R) 3700 DNA analyzer. *Tumori* 2001; 87:S40-S43

Adams SD, Krausa P, McGinnis M, Simonis TB, Stein J, Marincola FM. Practicality of high throughput HLA sequence-based typing. *ASHI Quarterly* 2001; 25:54-57.

Alter HJ. An unexpected link between HCV and platelets. *Blood* 2001; 98:2291

Anasetti C, Haagenson M, Kollman C, Matlack M, Anderlini P, Fischer J, Rowley S, Leitman S, Stroncek D, Wingard JR, Confer D. Transplantation of G-CSF-mobilized blood stem cells from unrelated donors. *Blood* 2001; 98:3561

Bettinotti MP, Marincola FM. HLA and cancer: immunogenetics in action. *ASHI Quarterly* 2001; 25:7-10.

Bishop MR, Marchigiani D, Kasten-Sportes C, Castro K, Carter C, Read E, Leitman S, Hou J, Gress R, Fowler D. Pre-transplant quantitation of host T-cells as a method to determine adequate host immune depletion for successful engraftment of T-cell depleted allografts after reduced-intensity conditioning. *Blood* 2001; 98:792

Bolan CD, Greer SE, Cecco SA, Oblitas JM, Rehak NN, Leitman SF. Comprehensive analysis of citrate effects during plateletpheresis in normal donors. *Transfusion* 2001; 41:1165-1171.

Bolan CD, Yau YY, Mason G, Browning J, Cathy CC, Leitman SF. Controlled study of changes in iron parameters during MCV-guided phlebotomy therapy for hereditary hemochromatosis (HH). *Blood* 2001; 98:250

Bolan CD, Cecco SA, Wesley RA, Yau YY, Horne M, Remaley AT, Childs RW, Barrett AJ, Rehak NN, Leitman SF. Controlled study of donor symptoms, citrate effects and responses to intravenous calcium in large volume leukapheresis (LVL). *Blood* 2001; 98:255

Bolan CD, Leitman SF, Griffith LM, Wesley RA, Procter JL, Stroncek DF, Barrett AJ, Childs RW. Delayed donor red cell chimerism and pure red cell aplasia following major ABO-incompatible nonmyeloablative hematopoietic stem cell transplantation. *Blood* 2001; 98:1687-1694.

Bolan CD, Yau YY, Cecco S, Rehak N, Leitman SF. Influence of gender on citrate-related effects during large volume leukapheresis (LVL). *Transfusion* 2001; 41:40S-41S.

Bolan CD, Childs RW, Procter JL, Barrett AJ, Leitman SF. Massive immune haemolysis after allogeneic peripheral blood stem cell transplantation with minor ABO incompatibility. *British Journal of Haematology* 2001; 112:787-795.

Bolan CD, Yau YY, Mason G, Browning J, Conry-Cantilena C, Leitman SF. MCV-guided phlebotomy for hemochromatosis (HH). *Transfusion* 2001; 41:72S-73S.

Bolan CD, Conry-Cantilena C, Mason G, Rouault TA, Leitman SF. MCV as a guide to phlebotomy therapy for hemochromatosis. *Transfusion* 2001; 41:819-827.

Caruccio L, Cipolone K, Procter JL, Stroncek D. A novel method using formamide for the elution of antibodies from erythrocytes. *Transfusion* 2001; 41:108S-109S.

Caruccio L, Bettinotti MP, Olsen A, Stroncek DF. Use of bioinformatics to identify the genomic structure of the gene encoding Polycythemia Rubra Vera-1 (PRV-1). *Blood* 2001; 98:1964

Chamberland ME, Alter HJ, Busch MP, Nemo G, Ricketts M. Emerging infectious disease issues in blood safety. *Emerging Infectious Diseases* 2001; 7:552-553.

Chambers D, Procter J, Muratova O, Cipolone K, Keister D, Shanks D, Magill A, Stroncek DF. Effects of in vitro *Plasmodium falciparum* exposure on RBC antigen expression. *Transfusion* 2001; 41:103S-104S.

Chang KM, Thimme R, Melpolder JJ, Oldach D, Pemberton J, Moorhead-Loudis J, McHutchison JG, Alter HJ, Chisari FV. Differential CD4(+) and CD8(+) T-cell responsiveness in hepatitis C virus infection. *Hepatology* 2001; 33:267-276.

Confer DL, Haagenson M, Anderlini P, Fischer J, Leitman S, Kollman C, Rowley SD, Stroncek DF, Wingard JR, Anasetti C. Collection of rhG-CSF-mobilized blood stem cells from 395 unrelated donors. *Blood* 2001; 98:3560

Dittmar K, Procter JL, Cipolone K, Njoroge JM, Miller J, Stroncek DF. Comparison of DATs using traditional tube agglutination to gel column and affinity column procedures. *Transfusion* 2001; 41:1258-1262.

Drew W, Alter HJ, Tegtmeier GE, Miner RC, Busch MP. Frequency and duration of plasma viremia in cytomegalovirus (CMV) seroconverters. *Transfusion* 2001; 41:22S

Dudley ME, Wunderlich J, Nishimura MI, Yu D, Yang JC, Topalian SL, Schwartzentruber DJ, Hwu P, Marincola FM, Sherry R, Leitman SF, Rosenberg SA. Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma. *Journal of Immunotherapy* 2001; 24:363-373.

Fogarty PF, Huhn RD, Nakamura R, Read EJ, Rick ME, Leitman SF, Greene A, Gratwohl A, Young NS, Barrett AJ, Dunbar CE. Intensive immunosuppression with high-dose cyclophosphamide and autologous CD34+selected hematopoietic cell support for chronic refractory autoimmune thrombocytopenia (AITP): A follow-up report. *Blood* 2001; 98:1855

Ghany MG, Alter H, Boone MH, Doo E, Khokar F, Heller T, Park Y, Liang TJ, Hoofnagle JH. False positive results using commercial RT-PCR for hepatitis C virus (HCV) RNA: Frequency and impact on clinical management. *Gastroenterology* 2001; 120:1892

Greco V, Cipolone K, Procter J, Stroncek DF. Detection of antibodies in acid eluates with gel microcolumns. *Transfusion* 2001; 41:109S

Griffith L, Klein HG. Immunohematology. In: Rich RR, Fleisher TA, Kotzin B, Shearer WT, Schroeder H, editors. *Clinical Immunology; Principles and Practice*. New York: Mosby, 2001:127.1-127.10

Hanada K, Perry-Lalley DM, Ohnmacht GA, Bettinotti MP, Yang JC. Identification of fibroblast growth factor-5 as an overexpressed antigen in multiple human adenocarcinomas. *Cancer Research* 2001; 61:5511-5516.

Harris DR, Gonin R, Alter HJ, Wright EC, Buskell ZJ, Hollinger FB, Seeff LB. The relationship of acute transfusion-associated hepatitis to the development of cirrhosis in the presence of alcohol abuse. *Annals of Internal Medicine* 2001; 134:120-124.

Horwitz ME, Barrett AJ, Brown MR, Carter CS, Childs R, Gallin JI, Gress RE, Holland SM, Linton GF, Miller JA, Leitman SF, Read EJ, Schermerhorn J, Malech HL. Treatment of chronic granulomatous disease with nonmyeloablative conditioning and a T-cell-depleted hematopoietic allograft. *New England Journal of Medicine* 2001; 344:881-888.

Kissel K, Santoso S, Hofmann C, Stroncek D, Bux J. Molecular basis of the neutrophil glycoprotein NB1 (CD177) involved in the pathogenesis of immune neutropenias and transfusion reactions. *European Journal of Immunology* 2001; 31:1301-1309.

Kissel K, Santoso S, Stroncek DF, Bux J. Molecular basis of the human neutrophil alloantigen HNA-2a (NB1, CD177). *Transfusion* 2001; 41:41S

Klein HG. Blood donation: Its more than comfort and convenience. *AABB News* 2001; Jan/Feb:2

Klein HG. Earthquake in America. *Transfusion* 2001; 41:1179-1180.

Klein HG. Rushing into the new millenium. *AABB News* 2001; Sept/Oct:1

Klein HG. Safety and availability: The CJD paradigm. *AABB News* 2001; Jul/Aug:2

Klein HG. The immunomodulatory effects of blood transfusion. *Tumori* 2001; 87:S17-S19

Klein HG. The transfusion timeline and current good health care practices. *AABB News* 2001; May/June:2

Klein HG. Will blood transfusion ever be safe enough? *Transfusion Medicine* 2001; 11:122-124.

Kondo T, Cortese I, Markovic-Plese S, Wandinger KP, Carter C, Brown M, Leitman S, Martin R. Dendritic cells signal T cells in the absence of exogenous antigen. *Nature Immunology* 2001; 2:932-938.

Lally KM, Mocellin S, Ohnmacht GA, Nielsen MB, Bettinotti M, Panelli MC, Monsurro V, Marincola FM. Unmasking cryptic epitopes after loss of immunodominant tumor antigen expression through epitope spreading. *International Journal of Cancer* 2001; 93:841-847.

Lazarus EF, Browning J, Norman J, Oblitas J, Leitman SF. Sustained decreases in platelet count associated with multiple, regular plateletpheresis donations. *Transfusion* 2001; 41:756-761.

Leitman SF, Sharon V, Noguchi CT, Schechter AN, Klein HG, Stroncek DF. Collection of sickle cell trait red cells by apheresis allows effective leukocyte reduction by filtration. *Blood* 2001; 98:3444

Leitman SF, Oblitas JM, Bolan CD. Crescendo angina during granulocytapheresis in a G-CSF-stimulated donor. *Transfusion* 2001; 41:36S

Leitman SF, Browning J, Mason G, Yau Y, Conry-Cantilena C, Bolan CD. Operational impact of using hemochromatosis (HH) subjects as allogeneic blood donors. *Transfusion* 2001; 41:21S

Lightfoot T, Gallelli J, Matsuo K, Kwon SW, Leitman SF, Stroncek DF. Evaluation of solutions for the storage of granulocyte colony-stimulating factor-mobilized granulocyte concentrates. *Vox Sanguinis* 2001; 80:106-111.

Lim JB, Provenzano M, Bettinotti M, Stroncek DF. Identification of a new candidate HLA-A3 restricted CMV epitope as a target antigen to induce specific CMV cytotoxic T lymphocytes. *Blood* 2001; 98:3244

Matsuo K, Procter JL, Chanock S, Stroncek DF. The expression of NA antigens in people with unusual Fc gamma receptor III genotypes. *Transfusion* 2001; 41:775-782.

Mocellin S, Wang E, Marincola FM. Cytokines and immune response in the tumor microenvironment. *Journal of Immunotherapy* 2001; 24:392-407.

Mocellin S, Ohnmacht GA, Wang E, Marincola FM. Kinetics of cytokine expression in melanoma metastases classifies immune responsiveness. *International Journal of Cancer* 2001; 93:236-242.

Mocellin S, Fetsch T, Abati T, Phan GQ, Wang J, Provenzano M, Stroncek D, Rosenberg SA, Marincola FM. Laser scanning cytometry evaluation of MART-1, gp100, and HLA-A2 expression in melanoma metastases. *Journal of Immunotherapy* 2001; 24:447-458.

Monsurro V, Nielsen MB, Perez-Diez A, Dudley ME, Wang E, Rosenberg SA, Marincola FM. Kinetics of TCR use in response to repeated epitope-specific immunization. *Journal of Immunology* 2001; 166:5817-5825.

Nakamura R, Cortez K, Childs R, Solomon S, Battiwalla M, Gill VJ, Read EJ, Leitman S, Bennett JE, Hensel N, Barrett J. Prevention of CMV disease by a prophylaxis-monitoring-early treatment (PME) using high-dose acyclovir, pp65 antigenemia, and ganciclovir: Elimination of CMV mortality and low risk in non-myeloablative transplant (NMT). *Blood* 2001; 98:1656

Nakamura R, Bahceci E, Read EJ, Leitman SF, Carter CS, Childs R, Dunbar CE, Gress R, Altemus R, Young NS, Barrett AJ. Transplant dose of CD34(+) and CD3(+) cells predicts outcome in patients with haematological malignancies undergoing T cell-depleted peripheral blood stem cell transplants with delayed donor lymphocyte add-back. *British Journal of Haematology* 2001; 115:95-104.

Ohnmacht GA, Phan GQ, Mavroukakis SA, Steinberg SM, Shea YR, Witebsky FG, McIntyre LS, Goodwin RS, Muehlbauer PM, Morton KE, Rogers-Freezer LJ, Seipp CA, Rosenberg SA, Marincola FM. A prospective, randomized, double-blind, placebo-controlled trial evaluating the effect of nystatin on the development of oral irritation in patients receiving high-dose intravenous interleukin-2. *Journal of Immunotherapy* 2001; 24:188-192.

Ohnmacht GA, Wang E, Mocellin S, Abati A, Filie A, Fetsch P, Riker AI, Kammula US, Rosenberg SA, Marincola FM. Short-term kinetics of tumor antigen expression in response to vaccination. *Journal of Immunology* 2001; 167:1809-1820.

Promrat K, McDermott DH, Gonzalez CM, Lessie MD, Merrell MN, Koziol D, Ghany M, Park Y, Alter HJ, Hoofnagle JH, Murphy PM, Liang TJ. Effect of CCR5 Delta 32 on HCV infection. *Hepatology* 2001; 34:225

Provenzano M, Lim JB, Bettinotti M, Mocellin S, Marincola FM, Stroncek DF. Matrix protein pp65(341-350), a peptide that induces HLA-restricted CMV-specific CTL in both HLA-A*2402 and A*0101 subjects. *Blood* 2001; 98:90

Ramirez CM, Yau YY, Mason G, Browning J, Conry-Cantilena C, Leitman SF, Bolan CD. Effect of iron burden and carefully controlled phlebotomy therapy on arthritic symptoms in hereditary hemochromatosis (HH). *Blood* 2001; 98:18

Read EJ. Development of hematopoietic stem cell standards. *Transfusion and Apheresis Science* 2001; 24:185-186.

Rezvani K, Mocellin S, Provenzano M, Melenhorst J, Hensel N, Fujiwara H, Sconocchia G, Stroncek D, Barrett J. Real time reverse transcriptase PCR can be used to demonstrate the presence of cytotoxic T lymphocytes against PR1 in healthy donors. *Blood* 2001; 98:5258

Seeff LB, Hollinger FB, Alter HJ, Wright EC, Cain CMB, Buskell ZJ, Ishak KG, Iber FL, Toro D, Samanta A, Koretz RL, Perrillo RP, Goodman ZD, Knodell RG, Gitnick G, Morgan TR, Schiff ER, Lasky S, Stevens C, Vlahcevic RZ, Weinshel E, Tanwadee T, Lin HJ, Barbosa L. Long-term mortality and morbidity of transfusion-associated non-A, non-B, and type C hepatitis: A national heart, lung, and blood institute collaborative study. *Hepatology* 2001; 33:455-463.

Seiter S, Monsurro V, Wunderlich J, Rosenberg S, Marincola F. MART-1/MelanA and gp100/PMel17 immunodominance revisited: Direct enumeration of frequency of melanoma differentiation antigen (MDA)-specific T-cells in tumor metastases TIL cultures. *Journal of Investigative Dermatology* 2001; 117:471

Shi PA, Pomper GJ, Metzger ME, Donahue RE, Leitman SF, Dunbar CE. Assessment of rapid remobilization intervals with G-CSF and SCF in murine and rhesus macaque models. *Transfusion* 2001; 41:1438-1444.

Shibata M, Hiroishi K, Ito T, Wang RYH, Yoshita M, Shih JWK, Alter HJ, Mitamura K. Presence of a novel SEN-virus in patients with liver diseases and blood donors in Japan. *Gastroenterology* 2001; 120:2825

Shibata M, Wang RYH, Yoshida M, Shih JWK, Alter HJ, Mitamura K. The presence of a newly identified infectious agent (SEN virus) in patients with liver diseases and in blood donors in Japan. *Journal of Infectious Diseases* 2001; 184:400-404.

Simone N, Fetsch P, Filie A, Marincola F, Simone C, Petricoin E, Liotta LA, Abati A. Proteomic evaluation of archival FNAs: New vistas in diagnoses. *Laboratory Investigation* 2001; 81:349

Solomon SR, Nakamura R, Read EJ, Leitman SF, Childs RW, Dunbar CE, Young NS, Barrett AJ. Is cyclosporine (CSA) necessary to prevent graft-versus-host- disease (GVHD) after T cell depleted peripheral blood stem cell transplantation (PBSCT)? *Blood* 2001; 98:1744

Stroncek D, Anderlini P. Mobilized PBPC concentrates: a maturing blood component. *Transfusion* 2001; 41:168-171.

Stroncek DF, Yau YY, Oblitas J, Leitman SF. Administration of G-CSF plus dexamethasone produces greater granulocyte concentrate yields while causing no more donor toxicity than G-CSF alone. *Transfusion* 2001; 41:1037-1044.

Stroncek DF, Njoroge JM, Procter JL, Griffith LM, Childs RW, Miller J. Flow cytometry is more sensitive at detecting RBC-associated C3d than the tube agglutination assay. *Blood* 2001; 98:249

Stroncek DF, Rainer T, Cipolone KM, Noguchi CT, Klein HG, Schechter AN, Leitman SF. Hemoglobin S polymerization in sickle cell trait RBCs prevents effective leukocyte reduction by filtration. *Blood* 2001; 98:3442

Stroncek DF, Carter LB, Procter JL, Dale JK, Straus SE. RBC autoantibodies in autoimmune lymphoproliferative syndrome. *Transfusion* 2001; 41:18-23.

Stroncek DF, Matthews C, Leitman SF. Same-day mobilization and collection of granulocytes. *Transfusion* 2001; 41:39S

Tanaka Y, Primi D, Wang RYH, Umemura T, Yeo AET, Mizokami M, Alter HJ, Shih JWK. Genomic and molecular evolutionary analysis of a newly identified infectious agent (SEN virus) and its relationship to the TT virus family. *Journal of Infectious Diseases* 2001; 183:359-367.

Tanaka Y, Mizokami M, Shih JW, Alter HJ. Timing the ancestry of hepatitis C virus genotype 1a strains in the United States. *Hepatology* 2001; 34:177

Umemura T, Alter HJ, Tanaka E, Yeo AET, Shih JWK, Orii K, Matsumoto A, Yoshizawa K, Kiyosawa K. Association between SEN virus infection and hepatitis C in Japan. *Journal of Infectious Diseases* 2001; 184:1246-1251.

Umemura T, Yeo AET, Sottini A, Moratto D, Tanaka Y, Wang RYH, Shih JWK, Donahue P, Primi D, Alter HJ. SEN virus infection and its relationship to transfusion-associated hepatitis. *Hepatology* 2001; 33:1303-1311.

Umemura T, Alter HJ, Tanaka E, Yeo AE, Shih JW, Orii K, Matsumoto A, Yoshizawa K, Kiyosawa K. SEN virus infection in high- and non-endemic areas for hepatitis C in Japan. *Hepatology* 2001; 34:1262

Umemura T, Tanaka Y, Kiyosawa K, Alter HJ, Shih JW. The evolutionary rate of SEN virus, a newly identified single- stranded circular DNA virus, is more similar to RNA viruses than classic DNA viruses. *Hepatology* 2001; 34:1857

Wang E, Marincola FM. cDNA arrays and the enigma of melanoma immune responsiveness. *Cancer Journal* 2001; 7:16-23.

Wang E, Panelli MC, Marincola FM. The impact of genomics on the biotechnology industry. *Expert Opinion on Biological Therapy* 2001; 1:749-751.

Wedemeyer H, He XS, Nascimbeni M, Davis AR, Greenberg HB, Alter H, Rehermann B. Impaired effector function of HCV-specific CD8+T cells in chronic hepatitis C virus infection. *Journal of Hepatology* 2001; 34:24-25.

84. Wilson LE, Umemura T, Astemborski J, Ray SC, Alter HJ, Strathdee SA, Vlahov D, Thomas DL. Dynamics of SEN virus infection among injection drug users. *Journal of Infectious Diseases* 2001; 184:1315-1319.

85. Wilson LE, Umemura T, Astemborski J, Ray SC, Alter HJ, Strathdee SA, Vlahov D, Thomas DL. Dynamics of SEN virus infection among injection drug users. *Clinical Infectious Diseases* 2001; 33:406

Wong ECC, Maher VE, Hines K, Lee J, Carter CS, Goletz T, Kopp W, Mackall CL, Berzofsky JA, Read EJ. Development of a clinical-scale method for generation of dendritic cells from PBMC for use in cancer immunotherapy. *Cytotherapy* 2001; 3:19-29.

Worley BS, van den Broeke LT, Goletz TJ, Pendleton CD, Daschbach EM, Thomas EK, Marincola FM, Helman LJ, Berzofsky JA. Antigenicity of fusion proteins from sarcoma-associated chromosomal translocations. *Cancer Research* 2001; 61:6868-6875.

Yeo AET, Tanaka Y, Pfeiffer R, Umemura T, Seal KH, Shih JWK, Alter HJ, Edlin BR, O'Brien TR. SEN viruses are common in injection drug users in San Francisco. *American Journal of Epidemiology* 2001; 153:1020

Yeo AET, Ghany M, Conry-Cantilena C, Melpolder JC, Kleiner DE, Shih JWK, Hoofnagle JH, Alter HJ. Stability of HCV-RNA level and its lack of correlation with disease severity in asymptomatic chronic hepatitis C virus carriers. *Journal of Viral Hepatitis* 2001; 8:256-263.

Zumberg MS, Procter JL, Lottenberg R, Kitchens CS, Klein HG. Autoantibody formation in the alloimmunized red blood cell recipient - Clinical and laboratory implications. *Archives of Internal Medicine* 2001; 161:285-290.